Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional DMARD use. Adalimumab is most used
Links:
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
In a phase I study that also included placebo-controlled efficacy testing, Western Ontario and
Read Article
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
Links:
Links:
A Mayo Clinic study shows that over three decades, anxiety and depression have become more common in individuals with rheumatoid arthritis (RA).
Data drawn from the Rochester Epidemiology Project identified incident adult RA (age
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
Read Article
Links:
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Reuters reports that a U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck failed to warn that patients taking alendronate for osteoporosis may be at increased the risk of atypical femoral fractures.
Read Article
A University of Mississippi-led comprehensive study of a disorder that affects 4.27 million Americans nationwide is revealing just how significant its burdens are on patients' financial well-being and quality of life. Patients with rheumatoid arthritis pay an average of $3,383 more per year
Read Article
A UK study shows biological and targeted synthetic DMARD use in newly diagnosed rheumatoid arthritis varies markedly by ethnicity, age and setting - "one-size-fits-all approach" does not apply.
Read Article
A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.
The recombinant zoster vaccine (RZV; or "Shingrix") was FDA approved In 2017 for
Read Article
Adults younger than age 45 with chronic, nonspecific lower back pain saw significant pain relief with a structured run-walk program in a randomized trial.
At the end of 12 weeks, participants in the program scored their pain level an average 15.3 points lower (95% CI 5.3-25.3), on a 100
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Today’s reports suggest where to look for help, especially with regard to pain.
Read Article
Links:
A population based screening program of patients with chronic inflammatory rheumatic diseases (IRD) demonstrates that systematic screening IRD patients for multimorbidity increased preventive interventions and reduced hospital admissions.
Read Article
